Rigel Pharmaceuticals, Inc.(RIGL)Earnings, Financials & Key RatiosRigel Pharmaceuticals, Inc. (RIGL) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company has achieved a positive net income of $8.7 million in 2026Q1, the current P/E of 1.99 and historical revenue volatility suggest that sustainable, organic earnings power remains unproven.
Rigel Pharmaceuticals, Inc. (RIGL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Rigel Pharmaceuticals, Inc. (RIGL) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.44vs $0.74-40.5% | $59Mvs $62M-5.7% |
| Q2 2026 | Mar 3, 2026 | $1.14vs $1.33-14.3% | $70Mvs $69M+1.6% |
| Q4 2025 | Nov 4, 2025 | $1.46vs $0.93+57.0% | $69Mvs $68M+1.5% |
| Q3 2025 | Aug 5, 2025 | $3.28vs $1.97+66.5% | $102Mvs $62M+63.2% |
Recent stock market news and headlines for Rigel Pharmaceuticals, Inc. (RIGL)
Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 She has resigned from Rigel's Board of Directors to join the company SOUTH SAN FRANCISCO, Calif., July 1, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the appointment of Alison L.
Rigel Pharmaceuticals trades at an attractive valuation after a 35% pullback, with a market cap just over $600 million. RIGL's growth strategy pivots on the Veppanu licensing deal, supplementing strong Tavalisse performance and recent product acquisitions. Q1 revenues rose 10% year-over-year to $58.8 million, but net product revenues rose 26%; management also maintained FY2026 sales guidance of $275–$290 million.
SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions.
Key metrics vs top competitors for Rigel Pharmaceuticals, Inc. (RIGL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $40.26 | $744.8M | 2.07 | 64.15% | 124.72% | 185.94% | — | |
| $9.50 | $497.36M | -2.10 | -92.84% | -260.92% | -49.88% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $33.70 | $3.31B | -5.78 | 20.13% | -91.03% | — | — | |
| $80.78 | $9.58B | 31.55 | 37.55% | 23.13% | 126.27% | — | |
| $85.44 | $7.09B | 10.98 | 114.51% | -22.58% | — | — |
Rigel Pharmaceuticals, Inc. (RIGL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Rigel Pharmaceuticals, Inc. (RIGL) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Apr 21, 2026·SEC
Mar 3, 2026·SEC
Get notified when RIGL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Rigel Pharmaceuticals, Inc. (RIGL) stock FAQ — growth, dividends, profitability & financials explained
Rigel Pharmaceuticals, Inc. (RIGL) reported $299.8M in revenue for fiscal year 2025. This represents a 3237% increase from $9.0M in 1999.
Rigel Pharmaceuticals, Inc. (RIGL) grew revenue by 64.1% over the past year. This is strong growth.
Yes, Rigel Pharmaceuticals, Inc. (RIGL) is profitable, generating $364.2M in net income for fiscal year 2025 (124.7% net margin).
Rigel Pharmaceuticals, Inc. (RIGL) has a return on equity (ROE) of 185.9%. This is excellent, indicating efficient use of shareholder capital.
Rigel Pharmaceuticals, Inc. (RIGL) generated $79.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
